• 1
    Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341:556562.MEDLINE
  • 2
    Seaberg EC, Belle SH, Beringer KC, Schivins JL, Detre KM. Long-term patient and retransplantation-free survival by selected recipient and donor characteristics: an update from the Pitt-UNOS Liver Transplant Registry. Clinical Transplants 1997:1528.
  • 3
    Satcher DA. Testimony to Congress, Committee on Government Reform and Oversight Subcommittee on Human Resources. 1998.
  • 4
    Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology 1997; 26(Suppl):15S20S.MEDLINE
  • 5
    Di Bisceglie AM. Hepatitis C. Lancet 1998; 351:351355.MEDLINE
  • 6
    Gross JB, Jr. Clinician's guide to hepatitis C. Mayo Clinic Proc 1998;73:355360; quiz 361.
  • 7
    Seeff LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, Hollinger FB, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group. N Engl J Med 1992; 327:19061911.MEDLINE
  • 8
    Tong MJ, el- Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332:14631466.MEDLINE
  • 9
    Serfaty L, Aumaitre H, Chazouilleres O, Bonnand AM, Rosmorduc O, Poupon RE, Poupon R, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998; 27:14351440.MEDLINE
  • 10
    Kondro W. Revised estimates of hepatitis C from tainted blood published [news]. Lancet 1998; 352:466.MEDLINE
  • 11
    Harwood HFD, Livermore G. The economic costs of alcohol and drug abuse in the United States 1992. Washington, DC: US Government Printing Office, 1998.
  • 12
    Anonymous. Comparative Analysis of HCUP and NHDS Inpatient Discharge Data. Technical Supplement 13, NIS Release 5. Rockville, MD: Agency for Health Care Policy and Research, 1999.
  • 13
    Iezzoni L. Risk Adjustment for Measuring Healthcare Outcomes. Chicago: Health Administration Press, 1997.
  • 14
    Knaus WA, Wagner DP, Draper EA, Zimmerman JE, Bergner M, Bastos PG, Sirio CA, et al. The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Chest 1991; 100:16191636.MEDLINE
  • 15
    Hoyert DL KK, Murphy SL. Death: Final Data for 1997. National Vital Statistics Reports. Vol. 47. Hyattsville, MD: National Center for Health Statistics, 1999.
  • 16
    Bonkovsky HL, Woolley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology 1999; 29:264270.MEDLINE
  • 17
    Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998; 27:209212.MEDLINE
  • 18
    Brown DM. Cost of Digestive Diseases in the United States. In: JEEverhart, ed. Digestive Diseases in the United States: Epidemiology and Impact. Washington, DC: US Government Printing Office, 1994:6776.
  • 19
    Kim WR, Poterucha JJ, Hermans JE, Therneau TM, Dickson ER, Evans RW, Gross JB, Jr, et al. Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C. Ann Int Med 1997; 127:866874.
  • 20
    Collier J, Heathcote J. Hepatitis C viral infection in the immunosuppressed patient. Hepatology 1998; 27:26.MEDLINE
  • 21
    Reddy KR, Hoofnagle JH, Tong MJ, Lee WM, Pockros P, Heathcote EJ, Albert D, et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology 1999; 30:787793.MEDLINE